Nephrologist with special interest in autoimmune glomerular diseases and transplantation
Joined August 2013
- Tweets24
- Following347
- Followers93
- Likes45
Pani Gopaluni retweeted
The APPLAUSE-IgAN trial confirms iptacopan as a disease modifying therapy for high-risk IgA nephropathy.
Key takeaways:
✅ ~50% reduction in eGFR decline rate
✅ 43% reduction in kidney failure risk (HR 0.57)
✅ Proteinuria reduction sustained at 24 months
✅ Vaccinate before starting : pneumococcal + meningococcal mandatory
✅ SGLT2i combination: promising signal
Barratt J et al. NEJM 2026
DOI: 10.1056/NEJMoa2600743
#IgANephropathy #Iptacopan #APPLAUSE #Nephrology
Pani Gopaluni retweeted
Delighted that FIND CKD has meet its primary endpoint. Fantastic news for patients with non-diabetic CKD, including those with GNs, including IgAN
Thank you to Bayer, all the investigators, study teams & patients who have made FIND-CKD possible
bayer.com/media/en-us/finere…
Pani Gopaluni retweeted
UBC Engineering professor elected to Canadian Academy of Engineering - News | UBC Applied Science: apsc.ubc.ca/news/2024/ubc-en…
Pani Gopaluni retweeted
Congratulations 👏 Dr Pani Gopaluni for the excellent Symposium on transplantation, very insightful on various aspects of kidney transplantation @HydNephForum @drmanishasahay @myadla @DrPSVali @srikanthnephro @kiranmai_ismal
Pani Gopaluni retweeted
SGLT2 inhibitors reduce CKD progression by ~40%, regardless of:
- Diabetes
- CKD aetiology
- Type of glomerular disease
And reduces AKI by ~20%
Presented by @NatalieStaplin on behalf of @Oxford_NDPH Renal Studies Group & SGLT2 Trialists Consortium (SMART-C)
#KidneyWk
Pani Gopaluni retweeted
Rupee at a record low of 79/$, what’s happening?
A dummies guide in this 🧵
Do ‘re-tweet’ & help us educate more investors (1/13)
#Investing #invest #StockMarket #RupeeVsDollar #RupeeSlideDebate
Pani Gopaluni retweeted
One of the pearls presented during #ERA22! An impressive study with a very important message – at Vanves, France
Pani Gopaluni retweeted
BIOVAS is an innovative clinical trial, designed here in Cambridge by @PaniGopaluni and Prof David Jayne – at Cambridge, England
A team from our hospitals is leading a new, national trial to look at the best treatment for vasculitis - and has recruited its first patient, 10 year old Eliska.
orlo.uk/kEAu8
#Research #Excellent #SignUpToScience
Pani Gopaluni retweeted
The golden age of kidney trials continues! EMPA-KIDNEY stopped early 4 efficacy: amazing collaborators report design & baseline data - watch out for final results late 2022! More hope for patients with #CKD. @ChristophWanne4 @RichardHaynes3 @adeeralevin @MartinLandray @DCRINews
🆕Design, recruitment & baseline characteristics of the EMPA-KIDNEY trial
🆓bit.ly/3ih4VLm🔓
👉EMPA-KIDNEY will evaluate the efficacy & safety of empagliflozin in a widely generalizable population of people with CKD at risk of kidney disease progression
@willkidney
Pani Gopaluni retweeted
New 'Year in Review' online! @AKronbichler and Rachel Jones look into advances in immune-mediated kidney disease in 2021.
go.nature.com/3GVPH9d
Pani Gopaluni retweeted
The #lupusnephritis management renaissance
doi.org/10.1016/j.kint.2021.…
@Meyaix @AnaMalvar4 @BradRovin
Pani Gopaluni retweeted
Hormonal Imbalance Explained by Dr. Himabindu youtu.be/iVPQxGlmfOI via @YouTube
Pani Gopaluni retweeted
Sites of actions of HLA class I and II within the immune system in autoimmune and renal disease from our Review by @nephrologista, @KitchingLab, @RossjohnLab and colleagues go.nature.com/2GxHVXa
Pani Gopaluni retweeted
New Review! Plant-based diets to manage the risks & complications of CKD by J Carrero, @Ailegonzalezo C Avesani, S Bakker, V Bellizzi, @PSkrunch, C Clase, A Cupisti, @espinosaangeles @MolinaPab, K Moreau, G Piccoli, A Post, S Sezer & @denisfouque1 @eraedta go.nature.com/37lrWXu
Pani Gopaluni retweeted
#ERAEDTA2020 #eraedta20 #RITAZERAM trial of maintenance #rituximab vs #azathioprine in #AASV #vasculitis - #RhonaSmith Very clear presentation - steroid tapered and then off. Long follow up off treatment @stephenmcadoo @vascuk @ukivas @THKC1 @megan_griffith1 @VersusArthritis
Pani Gopaluni retweeted
Prof. David Jayne will present on "A randomized, double-blind, active controlled study of AVACOPAN in anti-neutrophil cytoplasmic antibody-associated vasculitis" in the LBCT Symposium 05 in Room Gold Plenary. Don't miss it! #ERAEDTA20 #ERAEDTA #clinicaltrials
